During the recent session, Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)’s traded shares were 0.48 million, with the beta value of the company hitting 2.59. At the last check today, the stock’s price was $8.32, reflecting an intraday loss of -12.24% or -$1.16. The 52-week high for the CRBP share is $61.90, that puts it down -643.99 from that peak though still a striking -2.16% loss since the share price plummeted to a 52-week low of $8.50. The company’s market capitalization is $101.33M, and the average intraday trading volume over the past 10 days was 0.26 million shares, and the average trade volume was 261.96K shares over the past three months.
Corbus Pharmaceuticals Holdings Inc (CRBP) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CRBP has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.26.
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) trade information
Corbus Pharmaceuticals Holdings Inc (CRBP) registered a -12.24% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -12.24% in intraday trading to $8.32, hitting a weekly high. The stock’s 5-day price performance is -18.03%, and it has moved by -32.85% in 30 days. Based on these gigs, the overall price performance for the year is -62.18%. The short interest in Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) is 2.32 million shares and it means that shorts have 11.0 day(s) to cover.
The consensus price target of analysts on Wall Street is $50, which implies an increase of 83.36% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $35 and $74 respectively. As a result, CRBP is trading at a discount of -789.42% off the target high and -320.67% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 18.86%. While earnings are projected to return 58.52% in 2025, the next five years will return 18.47% per annum.
CRBP Dividends
Corbus Pharmaceuticals Holdings Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)’s Major holders
Corbus Pharmaceuticals Holdings Inc insiders own 1.76% of total outstanding shares while institutional holders control 106.47%, with the float percentage being 108.37%.
Also, the Mutual Funds coming in first place with the largest holdings of Corbus Pharmaceuticals Holdings Inc (CRBP) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Nov 30, 2024 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 371.62 shares. This amounts to just over 3.05 percent of the company’s overall shares, with a $3.1 million market value. The same data shows that the other fund manager holds slightly less at 329.22, or about 2.70% of the stock, which is worth about $2.74 million.
